Transplants With Unlicensed Preserved Cord Blood
- Cord blood transplants can treat cancers and other diseases in children and adults. The U.S. Food and Drug Administration (FDA) requires cord blood to be collected and stored under certain safety standards. However, most available cord blood units were collected before the FDA set these standards. These units may not meet FDA standards, but they do meet similar standards set and followed by the National Marrow Donor Program (NMDP). Cord blood units that do not meet the new FDA standards may be used for transplants only as part of a research study. Doctors want to allow people who need transplants to receive cord blood that meets NMDP standards but may not meet FDA standards.
- To allow selected cord blood units that do not meet current FDA standards to be used for transplant.
- Individuals who need cord blood units for transplant, and who best match cord blood units that are not FDA-licensed.
- Participants will provide consent to receive cord blood that meets NMDP standards but may not meet FDA standards.
- Participants will remain on the study for observation for up to 1 year after transplant, or until they withdraw from the study for personal or medical reasons.
Myelodysplastic Syndrome (MDS)
Severe Aplastic Anemia
Procedure: Cord Blood Transplant
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications|
- To examine the incidence of neutrophil recovery of greater than or equal to 500/mm (3) after unlicensed CBU transplant.
- Assess incidence of graft rejection, transmission of infection, serious infusion reactions.
- Determine 1 year survival.
- Assess cumulative incidence of acute GVHD (grades II to IV), (grades III to IV), and incidence of chronic GVHD.
|Study Start Date:||February 2012|
|Estimated Study Completion Date:||October 2036|
|Estimated Primary Completion Date:||October 2036 (Final data collection date for primary outcome measure)|
Procedure: Cord Blood Transplant
The requirement for licensure became part of the FDA final rules for Human Cells, Tissues, and Tissue-Based Products (HCT/Ps) (March 29, 2004 and May 25, 2005) in an effort to prevent transmission of communicable disease, minimize contamination and preserved integrity and function during processing, outline safety and effectiveness requirements for cells from unrelated donors or when HCT/Ps are more than minimally manipulated, assure labeling is clear accurate and not misleading and monitor and communicate with industry via establishment registration. However, as of October 20, 2011, those units that do not meet the manufacturing requirements for licensure can only be distributed for transplantation if the transplant will occur under an IND research protocol. These units are in current and future inventory at domestic and international cord blood banks that cannot be demonstrated to meet licensing requirements. In addition to the licensure guidance, the FDA published a guidance in August 2011 entitled Investigational New Drug Applications (INDs) for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications.
This study is an access and distribution protocol conducted by the National Marrow Donor Program (NMDP) for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients, in which sites wishing to receive NMDP unrelated cord blood units for treatment or research must participate with an locally IRB- approved protocol.
The primary objective of this study is to examine the incidence of neutrophil recovery of greater than or equal to 500/mm(3) after cord blood transplantation in a multi-institution setting using CBUs that are not Food and Drug Administration (FDA) licensed.
In patients receiving non-licensed CBU
- Assess incidence of graft rejection
- Assess incidence of transmission of infection
- Assess incidence of serious infusion reaction Determine 1 year survival after cord blood transplantation
- Assess cumulative incidence of acute graft vs. host disease (GVHD) grades II to IV and grades III to IV
- Assess cumulative incidence of chronic GVHD
- Determine CBU-derived engraftment
- Patients of any age with FDA-specified indications
- Signed informed consent (and assent when applicable)
- Patients who have licensed CBUs available
- Cord blood transplant recipients at international transplant centers
-Treatment description, including pre-transplant conditioning and GVHD prophylaxis, will occur per each transplant center s specification.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01553461
|Contact: Richard W Childs, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Richard W Childs, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|